Stanford MEDICINE Department of Psychiatry and Behavioral Sciences

Stanford Psychedelic Science Group

presents:

Psilocybin-assisted Therapy for Major Depressive Disorder

Dr. Jordan Sloshower, MD, MSc

Tuesday November 10
5:30pm PST

https://stanford.zoom.us/webinar/register/WN_4R09Y6-TRzK3kCaPBSstnA (Click here to register)

Abstract (adapted from UMass PSIG flyer):
Preliminary evidence suggests that psychedelic-assisted treatments have therapeutic potential across a range of mental disorders; psilocybin-assisted therapy was recently granted breakthrough status by the FDA as a treatment for Major Depressive Disorder (MDD). In this talk, Dr Jordan Sloshower will present the design and preliminary results of his study of psilocybin-assisted therapy for MDD. This research also investigates potential mechanisms of action, namely induction of neuroplasticity and psychological flexibility. He will also discuss how this study employs Acceptance and Commitment Therapy (ACT) as an overarching psychotherapeutic framework, including the rationale for selecting ACT and areas of potential synergism between ACT and psilocybin therapy.

Bio:
Jordan Sloshower, MD, MSc is a psychiatrist and researcher in the Department of Psychiatry at Yale University. He co-founded the Yale Psychedelic Science Group and is currently an investigator and therapist in two clinical trials of psilocybin-assisted therapy in the treatment of major depressive disorder. He is also a clinical investigator in MAPS' Expanded Access Program for MDMA-assisted therapy of PTSD.